智通财经APP获悉,3月5日,全球临床试验收录网站clinicaltrials显示,安进(AMGN.US)启动了AMG 133(Maridebart Cafraglutide,MariTide)的两项III期临床试验(MARITIME-1和MARITIME-2),标志着AMG 133进入III期开发阶段。
AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽偶联药物,由靶向葡萄糖依赖性促胰岛素释放多肽受体(GIPR)的全人源单抗偶联两个GLP-1类似物而成,通过抑制GIPR并激活GLP-1受体(GLP-1R)来发挥减少食物摄入和调节代谢进而减轻体重和降低血糖的作用。
AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.